Piper Sandler raises AnaptysBio stock price target to $95 from $67

Piper Sandler raised its AnaptysBio (ANAB) price target to $95 from $67 and maintained Overweight, while UBS also lifted its target to $90 and H.C. Wainwright reiterated a $66 Buy; five analysts raised earnings estimates. Key corporate actions: Board authorized up to $100M buyback and management will spin off biopharma into First Tracks Biotherapeutics (ticker TRAX) with a distribution set for April 20, 2026; First Tracks raised $80M in a private placement at $13.81/share. ANAB has rallied ~190% (InvestingPro cites 198%) over the last year and currently has a $1.66B market cap, and the firm highlighted JEMPERLI launch success and ANB033 opportunities in celiac disease and eosinophilic esophagitis. Clinical readouts: ANB033 Phase 1b in celiac expected Q4 2026 and eosinophilic esophagitis data mid-2027.

Analysis

Recent corporate actions create two separable investment narratives: (1) a near-to-intermediate term supply-demand and corporate-governance story that can re-rate the parent equity irrespective of clinical outcomes, and (2) a binary, higher-conviction clinical-development path whose outcomes will dominate valuation in 12–24 months. The near-term corporate flow will amplify volatility — buybacks and capital transfers typically tighten float and increase gamma as option desks and retail adjust, so price moves will be larger on incremental news than for a comparable market-cap biotech.

Mechanistically, the program targeting CD122 positions the molecule in an axis that touches both T-cell and eosinophil biology, which creates asymmetric upside if early human biomarkers move favorably but also creates binary downside if target engagement doesn't translate to histologic endpoints. Competitive entrants targeting downstream cytokines raise the bar for full market penetration; a successful Phase 1b that shows robust histologic benefit would convert a de-risked safety story into a rapid commercial optionality re-rating over 12–36 months.

Second-order effects matter: the separation of businesses will likely direct institutional flows away from the parent into the new standalone bio entity for several quarters, creating windows where parent shares are under-owned and more responsive to buyback execution. Conversely, the newly public spinco will compete for capital and analyst attention and is likely to trade at a meaningful discount to sum-of-parts for months, offering relative-value opportunities.

Key catalysts to monitor are quarterly cash disclosures (burn and committed capital), pre-IDE/meeting feedback from regulators, and early biomarker readouts; tail risks include trial failure, larger-than-expected capital needs at the spinco, or unfavorable regulatory guidance that could force dilution. Position sizing should assume >40% binary moves on negative clinical outcomes and 2–3x upside on a clean development path within two years.

Key Decisions for Investors

• Tactical long ANAB equity (size 2–4% of biotech sleeve) accumulated over 4–8 weeks to capture buyback-driven tightness; set stop-loss at 20% and target asymmetric take-profit at 60–100% over 12–24 months if clinical catalysts align.
• Buy a 12–18 month call spread to express pipeline upside with defined risk: long ANAB 12–18m ITM/near-ATM call, short a higher strike call to finance premium. Risk limited to premium; aim for 3:1 upside if positive Phase 1b and supportive commercial signals materialize.
• Pair trade around the spin: long parent (ANAB) / short spinco (new ticker) equal notional for 0–3 months surrounding distribution to isolate corporate action execution risk and capture potential mispricing of the new public vehicle. Keep position small and monitor lock-ups and insider selling windows.
• Hedge the binary clinical risk with 6–12 month puts (small hedge ~25% of long exposure) to protect against >40% downside from a negative readout or unexpected dilution; reduce/roll hedges if interim biomarker signals are positive.